Diamyd Medical AB (DMYD-B) Fair Value & Analysis
Healthcare · SE · Market cap 176M SEK (≈ $18.4M) · ISIN SE0005162880
What is Diamyd Medical AB really worth?
Below-average quality, trading 16% below our fair value of kr 1.23.
Risks
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 22 days ago
Share price −0.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A fairly wide model range (kr 0.8160 to kr 1.54) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 1.00 – kr 38.08 · fair‑value band kr 0.8160 – kr 1.54 · the kr 1.04 price screens below the kr 1.23 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Diamyd Medical AB (DMYD-B) currently trades at kr 1.04, while our model-based Fair Value estimate is kr 1.23, implying the stock looks roughly 15.6% undervalued today. The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Revenue grew 15.1% year over year. The balance sheet holds a net cash position of 277M SEK. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 0.8160 (bear case) to kr 1.54 (bull case); at kr 1.04, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −59% fair-value upside, at 19%, DMYD-B screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when DMYD-B reaches fair value
Put DMYD-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 25 · Market factors (momentum, volatility) 6
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II …
Full company description
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is headquartered in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Diamyd Medical AB reported revenue of 130K SEK in FY2025 versus 253K SEK in FY2021, a compound −15.3%/yr. Reported net income was −170M SEK in FY2025.
Watch DMYD-B: get an alert when its fair value changes →
Peer Group
Biotechnology · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE BNTX | $111.40 | $45.66 | −59% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare Diamyd Medical AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Diamyd Medical AB (DMYD-B) overvalued or undervalued?
What is the fair value of DMYD-B?
What is the quality score of DMYD-B?
What is the net profit margin of DMYD-B?
Watch Diamyd Medical AB in the live analysis
One click puts Diamyd Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.